{
  "symbol": "AMGN",
  "year": 2024,
  "period": "Q1",
  "curated_text": "Symbol: AMGN. Year: 2024. Period: Q1. ReportType: Q10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: Litigation Amgen Inc., Samsung Bioepis Co. Ltd., Amgen Inc., Amgen Manufacturing Limited LLC, District Court, Bioepis, Samsung Biologics Co., Ltd., Biologics, Bioepis, Samsung, FDA, a Biologics License Application, Amgen, Asserted, the New Jersey District Court, Samsung, Answer, Counterclaims, Complaint, Fresenius Kabi USA, LLC, Fresenius SwissBiosim GmbH, GmbH, Fresenius, BLA, ABP, the U.S. District Court, Regeneron, the U.S. Court of Appeals, the Federal Circuit, the Federal Circuit Court, Sensipar (Sensipar Plaintiffs, Delaware District Court, The Sensipar Plaintiffs, Regeneron Pharmaceuticals, Inc., the Delaware District Court, The Delaware District Court, CareFirst, Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., Amgen Manufacturing, Limited, Immunex Corporation, Roche, U.S. Tax Litigation, Related Matters Amgen Inc. & Subsidiaries, IRS, Company, the U.S. Tax Court, Shareholder Derivative Litigation, Amgen\u2019s Board, the Delaware Chancery Court, the Roofers Local No. 149 Pension Fund, ChemoCentryx, ANALYSIS OF FINANCIAL CONDITION, MD&A, SEC, EPS. Context excerpt: Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products. The complaint asserts infringement of the following 34 patents: U.S. Patent Nos. 7,364,736; 7,888,101; 7,928,205; 8,058,418; 8,247,210; 8,460,896; 8,680,248; 9,012,178; 9,320,816; 9,328,134; 9,359,435; 9,481,901; 10,106,829; 10,167,492; 10,227,627; 10,421,987; 10,513,723; 10,583,397; 10,655,156; 10,822,630; 10,894,972; 10,907,186; 11,098,079; 11,130,980; 11,254,963; 11,292,829; 11,299,760; 11,384,378; 11,427,848; 11,434,514;",
  "competition_summary": [
    {
      "competitor": "Litigation Amgen Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Samsung Bioepis Co. Ltd.",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Amgen Inc.",
      "mentions": 4,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Amgen Manufacturing Limited LLC",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "District Court",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Bioepis",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Samsung Biologics Co., Ltd.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Biologics",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Bioepis, Samsung",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "FDA",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "a Biologics License Application",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Amgen",
      "mentions": 20,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Asserted",
      "mentions": 4,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "the New Jersey District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Samsung",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Answer",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Counterclaims",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Complaint",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Fresenius Kabi USA",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "LLC",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Fresenius SwissBiosim GmbH",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "GmbH",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Fresenius",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "BLA",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "ABP",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "the U.S. District Court",
      "mentions": 4,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Regeneron",
      "mentions": 5,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "the U.S. Court of Appeals",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "the Federal Circuit",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "the Federal Circuit Court",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Sensipar (Sensipar Plaintiffs",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Delaware District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "The Sensipar Plaintiffs",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Regeneron Pharmaceuticals, Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "the Delaware District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "The Delaware District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "CareFirst",
      "mentions": 4,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Group Hospitalization and Medical Services, Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "CareFirst BlueChoice, Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Amgen Manufacturing, Limited",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Immunex Corporation",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Roche",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "U.S. Tax Litigation",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Related Matters Amgen Inc. & Subsidiaries",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "IRS",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Company",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "the U.S. Tax Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Shareholder Derivative Litigation",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "Amgen\u2019s Board",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "the Delaware Chancery Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "the Roofers Local No. 149 Pension Fund",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "ChemoCentryx",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "ANALYSIS OF FINANCIAL CONDITION",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "MD&A",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "SEC",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    },
    {
      "competitor": "EPS",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to mar"
    }
  ]
}